Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

EWTX
Edgewise Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open
Jul 21, 2026 1:48:59 PM EDT
39.59USD+2.010%(+0.78)211,119
39.48Bid   45.60Ask   6.12Spread
Pre-market
Jul 17, 2026 9:25:30 AM EDT
38.29USD-1.340%(-0.52)0
After-hours
Jul 17, 2026 4:00:30 PM EDT
39.76USD-0.025%(-0.01)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 6, 2022
07:10AM EST  JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $33   Benzinga
Jan 5, 2022
02:30PM EST  Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge   Benzinga
08:36AM EST  Edgewise Therapeutics, Inc., (EWTX) reported positive topline results from the BMD, or phase 1b, portion of a first-in-human phase 1 trial assessing EDG-5506, an orally administered small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy and BMD.   RTTNews
08:25AM EST  Edgewise Announces Positive Results From EDG-5506 Phase 1b Trial In Adults With Becker Muscular Dystroph   RTTNews
08:20AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets   Benzinga
08:09AM EST  Edgewise Therapeutics Announces Topline Results From EDG-5506 Phase 1b Clinical Trial In Adults With Becker Muscular Dystrophy; EDG-5506 Was Del Tolerated With No Serious Adverse Events Observed, Demonstrated Robust Target Engagement   Benzinga
08:00AM EST  Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)   Business Wire
Jan 2, 2022
03:30PM EST  The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week   Benzinga
Dec 15, 2021
09:19AM EST  Edgewise Therapeutics To Report Phase 1b Topline Results Of EDG-5506 In Individuals With Becker Muscular Dystrophy On Jan. 5, 2022   Benzinga
09:00AM EST  Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study   Business Wire
Nov 17, 2021
09:00AM EST  Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2   Business Wire
Nov 10, 2021
08:19AM EST  Edgewise Therapeutics Q3 Net Loss $12.9 Mln Or $0.26/shr Vs. Loss $3.6 Mln Prior Year   RTTNews
08:18AM EST  Edgewise Therapeutics Q3 EPS $(0.26) Up From $(3.68) YoY   Benzinga
08:00AM EST  Edgewise Therapeutics Reports Third Quarter 2021 Financial Results   Business Wire
Oct 28, 2021
07:29AM EDT  Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial   Benzinga
06:12AM EDT  Edgewise Therapeutics Announces Topline Results From The EDG-5506 Phase 1 Multiple Ascending Dose Study In Healthy Volunteers And Doses First Becker Muscular Dystrophy Patients   Benzinga
06:00AM EDT  Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients   Business Wire
Sep 14, 2021
09:00AM EDT  Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event on September 23   Business Wire
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
12:30PM EDT  Edgewise's Inherited Neuromuscular Disorder Candidate Receives FDA Fast Track Tag   Benzinga
09:05AM EDT  Edgewise Receives FDA Fast Track Designation For EDG-5506 For Treatment Of Individuals With Becker Muscular Dystrophy   RTTNews
09:01AM EDT  Edgewise Therapeutics Reports Received FDA Fast Track Designation For EDG-5506 For Treatment Of Individuals With Becker Muscular Dystophy   Benzinga
09:00AM EDT  Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)   Business Wire
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 9, 2021
09:14AM EDT  Edgewise Therapeutics Q2 EPS $(0.21) Up From $(7.43) YoY   Benzinga
09:10AM EDT  Edgewise Therapeutics Q2 Loss Widens To $10.4 Mln Or $0.21/shr From $4.0 Mln Prior Year   RTTNews
09:00AM EDT  Edgewise Therapeutics Reports Second Quarter 2021 Financial Results   Business Wire
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
09:00AM EDT  Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11   Business Wire
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 2, 2021
07:38AM EDT  The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures   Benzinga
Jun 22, 2021
09:14AM EDT  Edgewise Therapeutics To Present At PPMD Annual Conference And New Directions In Biology And Disease Of Skeletal Muscle Conference   Benzinga
09:00AM EDT  Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle Conference   Business Wire
Jun 1, 2021
09:00AM EDT  Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference   Business Wire
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
04:43PM EDT  Edgewise Therapeutics Q1 EPS $(0.14)   Benzinga
04:01PM EDT  Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights   Business Wire
May 4, 2021
09:41AM EDT  Edgewise Announces Publication Of Cross-sectional, retrospective Study On Duchenne Muscular Dystrophy   RTTNews
09:07AM EDT  Edgewise Therapeutics Highlights Publication Of Data Showing Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy   Benzinga
09:00AM EDT  Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy   Business Wire
Apr 27, 2021
09:04AM EDT  Edgewise Therapeutics Appoints Joanne Donovan As Chief Medical Officer   RTTNews
09:00AM EDT  Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer   Business Wire
Apr 20, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021   Benzinga
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
07:53AM EDT  SVB Leerink Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $34   Benzinga
07:35AM EDT  Wedbush Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $38   Benzinga
06:47AM EDT  JP Morgan Initiates Coverage On Edgewise Therapeutics with Overweight Rating, Announces Price Target of $34   Benzinga
Apr 19, 2021
10:16AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2021   Benzinga
06:28AM EDT  Goldman Sachs Initiates Coverage On Edgewise Therapeutics with Neutral Rating, Announces Price Target of $31   Benzinga
Apr 3, 2021
02:05PM EDT  Last Week's Notable Insider Buys: PennyMac Financial, Republic Services And More   Benzinga
Mar 30, 2021
04:01PM EDT  Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares   Business Wire
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 26, 2021
01:51PM EDT  Edgewise Therapeutics Shares Open For Trade At $27; IPO Priced At $16/Share   Benzinga
09:16AM EDT  Edgewise Therapeutics Shares Will Open For Quote At 11:25 a.m. EDT, Expected To Open For Trade After 11:35 a.m. EDT; IPO Priced At $16/Share   Benzinga
Mar 25, 2021
10:29PM EDT  Edgewise Therapeutics Prices IPO Of 11 Mln Shares At $16.00/shr   RTTNews
10:23PM EDT  Edgewise Therapeutics Announces Pricing of Initial Public Offering   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC